Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop- the- losers trials

被引:26
作者
Bowden, Jack [1 ]
Glimm, Ekkehard [2 ]
机构
[1] MRC Biostat Unit, Cambridge CB2 OSR, England
[2] Novartis Pharma AG, CH-4002 Basel, Switzerland
基金
英国医学研究理事会;
关键词
Bias-adjusted estimation; Drop-the-losers design; Treatment selection; UMVCUE; EARLY TERMINATION; CLINICAL-TRIALS; 2-STAGE; DESIGNS; BIOMARKER;
D O I
10.1002/bimj.201200245
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The two-stage drop-the-loser design provides a framework for selecting the most promising of K experimental treatments in stage one, in order to test it against a control in a confirmatory analysis at stage two. The multistage drop-the-losers design is both a natural extension of the original two-stage design, and a special case of the more general framework of Stallard & Friede () (Stat. Med. 27, 6209-6227). It may be a useful strategy if deselecting all but the best performing treatment after one interim analysis is thought to pose an unacceptable risk of dropping the truly best treatment. However, estimation has yet to be considered for this design. Building on the work of Cohen & Sackrowitz () (Stat. Prob. Lett. 8, 273-278), we derive unbiased and near-unbiased estimates in the multistage setting. Complications caused by the multistage selection process are shown to hinder a simple identification of the multistage uniform minimum variance conditionally unbiased estimate (UMVCUE); two separate but related estimators are therefore proposed, each containing some of the UMVCUEs theoretical characteristics. For a specific example of a three-stage drop-the-losers trial, we compare their performance against several alternative estimators in terms of bias, mean squared error, confidence interval width and coverage.
引用
收藏
页码:332 / 349
页数:18
相关论文
共 21 条
[1]  
[Anonymous], 2009, Computation of Multivariate Normal and t Probabilities
[2]   Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [J].
Barnes, Peter J. ;
Pocock, Stuart J. ;
Magnussen, Helgo ;
Iqbal, Amir ;
Kramer, Benjamin ;
Higgins, Mark ;
Lawrence, David .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2010, 23 (03) :165-171
[3]   Likelihood inference for a two-stage design with treatment selection [J].
Bebu, Ionut ;
Luta, George ;
Dragalin, Vladimir .
BIOMETRICAL JOURNAL, 2010, 52 (06) :811-822
[4]   Unbiased estimation of selected treatment means in two-stage trials [J].
Bowden, Jack ;
Glimm, Ekkehard .
BIOMETRICAL JOURNAL, 2008, 50 (04) :515-527
[5]   Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection [J].
Carreras, Maximo ;
Brannath, Werner .
STATISTICS IN MEDICINE, 2013, 32 (10) :1677-1690
[6]   2 STAGE CONDITIONALLY UNBIASED ESTIMATORS OF THE SELECTED MEAN [J].
COHEN, A ;
SACKROWITZ, HB .
STATISTICS & PROBABILITY LETTERS, 1989, 8 (03) :273-278
[7]  
EMERSON SS, 1990, BIOMETRIKA, V77, P875, DOI 10.2307/2337110
[8]   Adaptive trial designs: a review of barriers and opportunities [J].
Kairalla, John A. ;
Coffey, Christopher S. ;
Thomann, Mitchell A. ;
Muller, Keith E. .
TRIALS, 2012, 13
[9]   Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility [J].
Kimani, Peter K. ;
Todd, Susan ;
Stallard, Nigel .
STATISTICS IN MEDICINE, 2013, 32 (17) :2893-2910
[10]   Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futility [J].
Koopmeiners, Joseph S. ;
Feng, Ziding ;
Pepe, Margaret Sullivan .
STATISTICS IN MEDICINE, 2012, 31 (05) :420-435